{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T04:14:32Z","timestamp":1792556072000,"version":"4.5.0"},"reference-count":102,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,6,1]],"date-time":"2024-06-01T00:00:00Z","timestamp":1717200000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,5,14]],"date-time":"2024-05-14T00:00:00Z","timestamp":1715644800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["DISC2-11157"],"award-info":[{"award-number":["DISC2-11157"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000900","name":"California Institute for Regenerative Medicine","doi-asserted-by":"publisher","award":["TRAN1-12250"],"award-info":[{"award-number":["TRAN1-12250"]}],"id":[{"id":"10.13039\/100000900","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007185","name":"UCLA","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007185","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000005","name":"U.S. Department of Defense","doi-asserted-by":"publisher","award":["CA200456"],"award-info":[{"award-number":["CA200456"]}],"id":[{"id":"10.13039\/100000005","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Molecular Therapy"],"published-print":{"date-parts":[[2024,6]]},"DOI":"10.1016\/j.ymthe.2024.04.005","type":"journal-article","created":{"date-parts":[[2024,4,6]],"date-time":"2024-04-06T17:47:08Z","timestamp":1712425628000},"page":"1849-1874","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":72,"title":["Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy"],"prefix":"10.1016","volume":"32","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9858-300X","authenticated-orcid":false,"given":"Yan-Ruide","family":"Li","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yang","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaji","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yichen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Derek","family":"Lee","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enbo","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhe","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu Jeong","family":"Kim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kuangyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Fang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zibai","family":"Lyu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuning","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanxin","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinjian","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tiffany","family":"Husman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jae Min","family":"Cho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tzung","family":"Hsiai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jin J.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pin","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benjamin R.","family":"Puliafito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah M.","family":"Larson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lili","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ymthe.2024.04.005_bib1","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1126\/science.aar6711","article-title":"CAR T\u00a0cell immunotherapy for human cancer","volume":"359","author":"June","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.04.005_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41408-021-00459-7","article-title":"CAR-T cell therapy: current limitations and potential strategies","volume":"11","author":"Sterner","year":"2021","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ymthe.2024.04.005_bib3","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1038\/s41586-023-05707-3","article-title":"CAR immune cells: design principles, resistance and the next generation","volume":"614","author":"Labanieh","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.04.005_bib4","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond","volume":"28","author":"Finck","year":"2022","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib5","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.stem.2023.02.009","article-title":"Advancing cell-based cancer immunotherapy through stem cell engineering","volume":"30","author":"Li","year":"2023","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.04.005_bib6","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1146\/annurev-med-062315-120245","article-title":"CAR T Cell Therapy for Solid Tumors","volume":"68","author":"Newick","year":"2017","journal-title":"Annu. Rev. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1038\/s41586-023-06243-w","article-title":"CAR T therapy beyond cancer: the evolution of a living drug","volume":"619","author":"Baker","year":"2023","journal-title":"Nature"},{"key":"10.1016\/j.ymthe.2024.04.005_bib8","doi-asserted-by":"crossref","first-page":"1885","DOI":"10.1016\/S0140-6736(20)32334-5","article-title":"Genome-edited, donor-derived allogeneic anti-CD19 chimeric antigen receptor T\u00a0cells in paediatric and adult B-cell acute lymphoblastic leukaemia: results of two phase 1 studies","volume":"396","author":"Benjamin","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ymthe.2024.04.005_bib9","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1038\/s41551-022-00915-0","article-title":"Generation of T-cell-receptor-negative CD8\u03b1\u03b2-positive CAR T\u00a0cells from T-cell-derived induced pluripotent stem cells","volume":"6","author":"van der Stegen","year":"2022","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2024.04.005_bib10","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.3389\/fimmu.2017.01178","article-title":"Natural Killer T Cells in Cancer Immunotherapy","volume":"8","author":"Nair","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib11","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1038\/nri3174","article-title":"Targeting natural killer cells and natural killer T\u00a0cells in cancer","volume":"12","author":"Vivier","year":"2012","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib12","doi-asserted-by":"crossref","first-page":"409","DOI":"10.3389\/fimmu.2013.00409","article-title":"NKT cells as an ideal anti-tumor immunotherapeutic","volume":"4","author":"Fujii","year":"2013","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib13","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1038\/s41591-020-1074-2","article-title":"Anti-GD2 CAR-NKT cells in patients with relapsed or refractory neuroblastoma: an interim analysis","volume":"26","author":"Heczey","year":"2020","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib14","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/nri3369","article-title":"Invariant natural killer T\u00a0cells: an innate activation scheme linked to diverse effector functions","volume":"13","author":"Brennan","year":"2013","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib15","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","article-title":"Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results","volume":"29","author":"Heczey","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib16","doi-asserted-by":"crossref","first-page":"869","DOI":"10.1182\/blood.2022016201","article-title":"Natural killer T\u00a0cells and other innate-like T lymphocytes as emerging platforms for allogeneic cancer cell therapy","volume":"141","author":"Courtney","year":"2023","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.04.005_bib17","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1146\/annurev.immunol.25.022106.141711","article-title":"The biology of NKT cells","volume":"25","author":"Bendelac","year":"2007","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib18","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1038\/s41571-021-00476-2","article-title":"Immunogenicity of CAR T\u00a0cells in cancer therapy","volume":"18","author":"Wagner","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib19","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1016\/j.ymthe.2022.11.019","article-title":"Mucosal-associated invariant T\u00a0cells for cancer immunotherapy","volume":"31","author":"Li","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.04.005_bib20","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.stem.2015.03.011","article-title":"New cell sources for T\u00a0cell engineering and adoptive immunotherapy","volume":"16","author":"Themeli","year":"2015","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.04.005_bib21","article-title":"Development of allogeneic HSC-engineered iNKT cells for off-the-shelf cancer immunotherapy","volume":"2","author":"Li","year":"2021","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib22","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1161\/CIRCRESAHA.117.306290","article-title":"Efficient gene disruption in cultured primary human endothelial cells by CRISPR\/Cas9","volume":"117","author":"Abrahimi","year":"2015","journal-title":"Circ. Res."},{"key":"10.1016\/j.ymthe.2024.04.005_bib23","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1158\/1078-0432.CCR-16-1300","article-title":"Multiplex genome editing to generate universal CAR T\u00a0cells resistant to PD1 inhibition","volume":"23","author":"Ren","year":"2017","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.04.005_bib24","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1126\/science.8016643","article-title":"Regulation of MHC class II expression by interferon-\u03b3 mediated by the transactivator gene CIITA","volume":"265","author":"Steimle","year":"1994","journal-title":"Science"},{"key":"10.1016\/j.ymthe.2024.04.005_bib25","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.stem.2019.08.004","article-title":"Development of Hematopoietic Stem Cell-Engineered Invariant Natural Killer T Cell Therapy for Cancer","volume":"25","author":"Zhu","year":"2019","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.ymthe.2024.04.005_bib26","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1182\/blood-2018-99-112786","article-title":"Durable Remission Achieved from Bcma-Directed CAR-T Therapy Against Relapsed or Refractory Multiple Myeloma","volume":"132","author":"Liu","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.04.005_bib27","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1016\/j.trecan.2021.08.004","article-title":"Engineering stem cells for cancer immunotherapy","volume":"7","author":"Li","year":"2021","journal-title":"Trends Cancer"},{"key":"10.1016\/j.ymthe.2024.04.005_bib28","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1038\/nri2116","article-title":"Control points in NKT-cell development","volume":"7","author":"Godfrey","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib29","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1084\/jem.20011908","article-title":"Distinct functional lineages of human V\u03b124 natural killer T\u00a0cells","volume":"195","author":"Lee","year":"2002","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib30","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1084\/jem.20011786","article-title":"Functionally distinct subsets of CD1d-restricted natural killer T\u00a0cells revealed by CD1d tetramer staining","volume":"195","author":"Gumperz","year":"2002","journal-title":"J.\u00a0Exp. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib31","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1038\/s41577-019-0200-1","article-title":"Engineering universal cells that evade immune detection","volume":"19","author":"Lanza","year":"2019","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib32","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/s41551-018-0235-9","article-title":"Programming CAR-T cells to kill cancer","volume":"2","author":"Labanieh","year":"2018","journal-title":"Nat. Biomed. Eng."},{"key":"10.1016\/j.ymthe.2024.04.005_bib33","doi-asserted-by":"crossref","first-page":"1355","DOI":"10.3389\/fimmu.2017.01355","article-title":"Invariant natural killer T\u00a0cells in immune regulation of blood cancers: Harnessing their potential in immunotherapies","volume":"8","author":"Lam","year":"2017","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib34","doi-asserted-by":"crossref","first-page":"367","DOI":"10.3389\/fimmu.2018.00367","article-title":"The Role of Natural Killer T Cells in Cancer-A Phenotypical and Functional Approach","volume":"9","author":"Krijgsman","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib35","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1146\/annurev.immunol.23.021704.115742","article-title":"Toward an understanding of NKT cell biology: progress and paradoxes","volume":"23","author":"Kronenberg","year":"2005","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib36","article-title":"Tumor-Localized Administration of \u03b1-GalCer to Recruit Invariant Natural Killer T Cells and Enhance Their Antitumor Activity against Solid Tumors","volume":"23","author":"Li","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.04.005_bib37","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/s41587-019-0016-3","article-title":"Hypoimmunogenic derivatives of induced pluripotent stem cells evade immune rejection in fully immunocompetent allogeneic recipients","volume":"37","author":"Deuse","year":"2019","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib38","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1111\/tan.12564","article-title":"A future with less HLA: potential clinical applications of HLA-universal cells","volume":"85","author":"Figueiredo","year":"2015","journal-title":"Tissue Antigens"},{"key":"10.1016\/j.ymthe.2024.04.005_bib39","first-page":"249","article-title":"FDA approves second BCMA-targeted CAR-T cell therapy","volume":"21","author":"Mullard","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.04.005_bib40","doi-asserted-by":"crossref","first-page":"2498","DOI":"10.1182\/blood-2008-06-161281","article-title":"Regulation of multiple myeloma survival and progression by CD1d","volume":"113","author":"Spanoudakis","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.04.005_bib41","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1038\/s41571-019-0297-y","article-title":"Engineering strategies to overcome the current roadblocks in CAR T\u00a0cell therapy","volume":"17","author":"Rafiq","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib42","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib43","doi-asserted-by":"crossref","first-page":"1237","DOI":"10.1158\/2326-6066.CIR-18-0940","article-title":"Systemic Interferon-\u03b3 Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial","volume":"7","author":"Zhang","year":"2019","journal-title":"Cancer Immunol. Res."},{"key":"10.1016\/j.ymthe.2024.04.005_bib44","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1186\/s40364-020-00228-x","article-title":"Roles of IFN-\u03b3 in tumor progression and regression: a review","volume":"8","author":"Jorgovanovic","year":"2020","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ymthe.2024.04.005_bib45","article-title":"Targeting Immunosuppressive Tumor-Associated Macrophages Using Innate T Cells for Enhanced Antitumor Reactivity","volume":"14","author":"Li","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2024.04.005_bib46","article-title":"An Ex\u00a0Vivo 3D Tumor Microenvironment-Mimicry Culture to Study TAM Modulation of Cancer Immunotherapy","volume":"11","author":"Li","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.04.005_bib47","article-title":"Target tumor microenvironment by innate T\u00a0cells","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib48","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1111\/imr.12233","article-title":"Targeting the bone marrow microenvironment in multiple myeloma","volume":"263","author":"Kawano","year":"2015","journal-title":"Immunol. Rev."},{"key":"10.1016\/j.ymthe.2024.04.005_bib49","doi-asserted-by":"crossref","first-page":"7627","DOI":"10.3390\/ijms23147627","article-title":"Targeting the Microenvironment for Treating Multiple Myeloma","volume":"23","author":"Neumeister","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.04.005_bib50","article-title":"Tumor-associated macrophages in multiple myeloma: Advances in biology and therapy","volume":"10","author":"Sun","year":"2022","journal-title":"J.\u00a0Immunother. Cancer"},{"key":"10.1016\/j.ymthe.2024.04.005_bib51","article-title":"Profiling ovarian cancer tumor and microenvironment during disease progression for cell-based immunotherapy design","volume":"26","author":"Li","year":"2023","journal-title":"iScience"},{"key":"10.1016\/j.ymthe.2024.04.005_bib52","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1016\/j.semcancer.2008.03.004","article-title":"Macrophage polarization in tumour progression","volume":"18","author":"Sica","year":"2008","journal-title":"Semin. Cancer Biol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173090","article-title":"Macrophage M1\/M2 polarization","volume":"877","author":"Yunna","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib54","doi-asserted-by":"crossref","DOI":"10.3390\/v11020168","article-title":"Myeloid Cells during Viral Infections and Inflammation","volume":"11","author":"Stegelmeier","year":"2019","journal-title":"Viruses"},{"key":"10.1016\/j.ymthe.2024.04.005_bib55","article-title":"Macrophage: Key player in the pathogenesis of autoimmune diseases","volume":"14","author":"Yang","year":"2023","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib56","doi-asserted-by":"crossref","first-page":"4815","DOI":"10.1182\/blood-2009-11-253534","article-title":"Bone marrow macrophages maintain hematopoietic stem cell (HSC) niches and their depletion mobilizes HSCs","volume":"116","author":"Winkler","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.04.005_bib57","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1146\/annurev-immunol-102119-073227","article-title":"Current Concepts and Advances in Graft-Versus-Host Disease Immunology","volume":"39","author":"Hill","year":"2021","journal-title":"Annu. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib58","doi-asserted-by":"crossref","first-page":"3041","DOI":"10.3389\/fimmu.2018.03041","article-title":"Strategies for Enhancing and Preserving Anti-leukemia Effects Without Aggravating Graft-Versus-Host Disease","volume":"9","author":"Chang","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib59","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aat8410","article-title":"Graft-versus-host disease, but not graft-versus-leukemia immunity, is mediated by GM-CSF-licensed myeloid cells","volume":"10","author":"Tugues","year":"2018","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib60","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1038\/nri2000","article-title":"Graft-versus-host disease","volume":"7","author":"Shlomchik","year":"2007","journal-title":"Nat. Rev. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib61","article-title":"Genetic engineering strategies to enhance antitumor reactivity and reduce alloreactivity for allogeneic cell-based cancer therapy","volume":"10","author":"Chen","year":"2023","journal-title":"Front. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib62","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24044084","article-title":"Graft-versus-Host Disease Modulation by Innate T Cells","volume":"24","author":"Fang","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ymthe.2024.04.005_bib63","doi-asserted-by":"crossref","first-page":"6242","DOI":"10.4049\/jimmunol.178.10.6242","article-title":"Host NKT Cells Can Prevent Graft-versus-Host Disease and Permit Graft Antitumor Activity after Bone Marrow Transplantation","volume":"178","author":"Pillai","year":"2007","journal-title":"J.\u00a0Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib64","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1038\/s41591-018-0041-7","article-title":"CAR T\u00a0cell-induced cytokine release syndrome is mediated by macrophages and abated by IL-1 blockade letter","volume":"24","author":"Giavridis","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib65","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1182\/blood-2018-10-881722","article-title":"GM-CSF inhibition reduces cytokine release syndrome and neuroinflammation but enhances CAR-T cell function in xenografts","volume":"133","author":"Sterner","year":"2019","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.04.005_bib66","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/s41591-018-0036-4","article-title":"Monocyte-derived IL-1 and IL-6 are differentially required for cytokine-release syndrome and neurotoxicity due to CAR T\u00a0cells","volume":"24","author":"Norelli","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib67","article-title":"Preclinical and clinical studies of CAR-NK-cell therapies for malignancies","volume":"13","author":"Li","year":"2022","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib68","doi-asserted-by":"crossref","first-page":"1769","DOI":"10.1016\/j.ymthe.2017.06.012","article-title":"Engineering Natural Killer Cells for Cancer Immunotherapy","volume":"25","author":"Rezvani","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.04.005_bib69","doi-asserted-by":"crossref","DOI":"10.4161\/onci.28147","article-title":"Are natural killer cells superior CAR drivers?","volume":"3","author":"Klingemann","year":"2014","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.ymthe.2024.04.005_bib70","doi-asserted-by":"crossref","first-page":"5173","DOI":"10.1158\/0008-5472.CAN-14-0376","article-title":"HSV-sr39TK positron emission tomography and suicide gene elimination of human hematopoietic stem cells and their progeny in humanized mice","volume":"74","author":"Gschweng","year":"2014","journal-title":"Cancer Res."},{"key":"10.1016\/j.ymthe.2024.04.005_bib71","doi-asserted-by":"crossref","first-page":"1249","DOI":"10.1182\/blood.V97.5.1249.h8001249_1249_1257","article-title":"A Fas-based suicide switch in human T\u00a0cells for the treatment of graft-versus-host disease","volume":"97","author":"Thomis","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.04.005_bib72","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.omtm.2021.03.002","article-title":"Improved safety of induced pluripotent stem cell-derived antigen-presenting cell-based cancer immunotherapy","volume":"21","author":"Mashima","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/j.ymthe.2024.04.005_bib73","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1056\/NEJMoa1106152","article-title":"Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy","volume":"365","author":"Di Stasi","year":"2011","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib74","doi-asserted-by":"crossref","first-page":"1365","DOI":"10.1038\/s41417-020-00284-3","article-title":"Overcoming target epitope masking resistance that can occur on low-antigen-expresser AML blasts after IL-1RAP chimeric antigen receptor T\u00a0cell therapy using the inducible caspase 9 suicide gene safety switch","volume":"28","author":"Warda","year":"2021","journal-title":"Cancer Gene Ther."},{"key":"10.1016\/j.ymthe.2024.04.005_bib75","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.3390\/cancers12092567","article-title":"The landscape of car-t cell clinical trials against solid tumors\u2014a comprehensive overview","volume":"12","author":"Schaft","year":"2020","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.ymthe.2024.04.005_bib76","doi-asserted-by":"crossref","DOI":"10.3390\/cells10123497","article-title":"Development of Stem Cell-Derived Immune Cells for Off-the-Shelf Cancer Immunotherapies","volume":"10","author":"Li","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ymthe.2024.04.005_bib77","doi-asserted-by":"crossref","first-page":"5199","DOI":"10.1073\/pnas.95.9.5199","article-title":"HLA-E is a major ligand for the natural killer inhibitory receptor CD94\/NKG2A","volume":"95","author":"Lee","year":"1998","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.04.005_bib78","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1182\/blood-2018-99-111356","article-title":"Preliminary Data on Safety, Cellular Kinetics and Anti-Leukemic Activity of UCART19, an Allogeneic Anti-CD19 CAR T-Cell Product, in a Pool of Adult and Pediatric Patients with High-Risk CD19+ Relapsed\/Refractory B-Cell Acute Lymphoblastic Leukemia","volume":"132","author":"Benjamin","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.04.005_bib79","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaz5618","article-title":"iPSC-derived NK cells maintain high cytotoxicity and enhance in\u00a0vivo tumor control in concert with T\u00a0cells and anti\u2013PD-1 therapy","volume":"12","author":"Cichocki","year":"2020","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib80","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1056\/NEJMoa1910607","article-title":"Use of CAR-Transduced Natural Killer Cells in CD19-Positive Lymphoid Tumors","volume":"382","author":"Liu","year":"2020","journal-title":"N.\u00a0Engl. J. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib81","doi-asserted-by":"crossref","first-page":"e833","DOI":"10.1016\/S2352-3026(22)00245-9","article-title":"UCART19, a first-in-class allogeneic anti-CD19 chimeric antigen receptor T-cell therapy for adults with relapsed or refractory B-cell acute lymphoblastic leukaemia (CALM): a phase 1, dose-escalation trial","volume":"9","author":"Benjamin","year":"2022","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib82","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1038\/s41591-022-02182-7","article-title":"Allogeneic BCMA-targeting CAR T\u00a0cells in relapsed\/refractory multiple myeloma: phase 1\u00a0UNIVERSAL trial interim results","volume":"29","author":"Mailankody","year":"2023","journal-title":"Nat. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib83","doi-asserted-by":"crossref","first-page":"1807","DOI":"10.1038\/s41587-022-01377-0","article-title":"Frequent aneuploidy in primary human T\u00a0cells after CRISPR-Cas9 cleavage","volume":"40","author":"Nahmad","year":"2022","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib84","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/s41573-019-0051-2","article-title":"\u201cOff-the-shelf\u201d allogeneic CAR T\u00a0cells: development and challenges","volume":"19","author":"Depil","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ymthe.2024.04.005_bib85","article-title":"Engineering Induced Pluripotent Stem Cells for Cancer Immunotherapy","volume":"14","author":"Zhou","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.ymthe.2024.04.005_bib86","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1182\/blood.2019000621","article-title":"Pluripotent stem cell-derived NK cells with high-affinity noncleavable CD16a mediate improved antitumor activity","volume":"135","author":"Zhu","year":"2020","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.04.005_bib87","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1182\/blood-2021-148654","article-title":"Off-the-Shelf, Multiplexed-Engineered iPSC-Derived NK Cells Mediate Potent Multi-Antigen Targeting of B-Cell Malignancies with Reduced Cytotoxicity Against Healthy B Cells","volume":"138","author":"Cichocki","year":"2021","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.04.005_bib88","article-title":"iPSC-derived hypoimmunogenic tissue resident memory T\u00a0cells mediate robust anti-tumor activity against cervical cancer","volume":"4","author":"Furukawa","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib89","first-page":"1","volume":"31","year":"2023","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.04.005_bib90","article-title":"Unedited allogeneic iNKT cells show extended persistence in MHC-mismatched canine recipients","volume":"4","author":"Rotolo","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.ymthe.2024.04.005_bib91","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1186\/s13045-021-01209-9","article-title":"Born to survive: how cancer cells resist CAR T\u00a0cell therapy","volume":"14","author":"Lemoine","year":"2021","journal-title":"J.\u00a0Hematol. Oncol."},{"key":"10.1016\/j.ymthe.2024.04.005_bib92","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1007\/s12015-019-09901-7","article-title":"Solid Tumors Challenges and New Insights of CAR T Cell Engineering","volume":"15","author":"Tahmasebi","year":"2019","journal-title":"Stem Cell Rev. Rep."},{"key":"10.1016\/j.ymthe.2024.04.005_bib93","article-title":"Tumor-associated macrophages: potential therapeutic strategies and future prospects in cancer","volume":"9","author":"Li","year":"2021","journal-title":"J.\u00a0Immunother. Can."},{"key":"10.1016\/j.ymthe.2024.04.005_bib94","doi-asserted-by":"crossref","DOI":"10.1002\/adma.202002054","article-title":"Engineering Macrophages for Cancer Immunotherapy and Drug Delivery","volume":"32","author":"Xia","year":"2020","journal-title":"Adv. Mater."},{"key":"10.1016\/j.ymthe.2024.04.005_bib95","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1136\/gutjnl-2015-310514","article-title":"Targeting of tumour-infiltrating macrophages via CCL2\/CCR2 signalling as a therapeutic strategy against hepatocellular carcinoma","volume":"66","author":"Li","year":"2017","journal-title":"Gut"},{"key":"10.1016\/j.ymthe.2024.04.005_bib96","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1038\/s41467-021-20893-2","article-title":"CAR-T cell-mediated depletion of immunosuppressive tumor-associated macrophages promotes endogenous antitumor immunity and augments adoptive immunotherapy","volume":"12","author":"Rodriguez-Garcia","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ymthe.2024.04.005_bib97","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","article-title":"NKT Cells Coexpressing a GD2-Specific Chimeric Antigen Receptor and IL15 Show Enhanced In\u00a0Vivo Persistence and Antitumor Activity against Neuroblastoma","volume":"25","author":"Xu","year":"2019","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ymthe.2024.04.005_bib98","doi-asserted-by":"crossref","first-page":"4247","DOI":"10.1182\/blood-2004-11-4564","article-title":"An inducible caspase 9 safety switch for T-cell therapy","volume":"105","author":"Straathof","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ymthe.2024.04.005_bib99","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1038\/mt.2013.8","article-title":"Allelic exclusion and peripheral reconstitution by TCR transgenic T\u00a0cells arising from transduced human hematopoietic stem\/progenitor cells","volume":"21","author":"Giannoni","year":"2013","journal-title":"Mol. Ther."},{"key":"10.1016\/j.ymthe.2024.04.005_bib100","doi-asserted-by":"crossref","first-page":"1523","DOI":"10.1073\/pnas.1424877112","article-title":"Genetic engineering of hematopoietic stem cells to generate invariant natural killer T\u00a0cells","volume":"112","author":"Smith","year":"2015","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ymthe.2024.04.005_bib101","doi-asserted-by":"crossref","first-page":"2899","DOI":"10.1182\/bloodadvances.2019001346","article-title":"CRISPR-based screens uncover determinants of immunotherapy response in multiple myeloma","volume":"4","author":"Ramkumar","year":"2020","journal-title":"Blood Adv."},{"key":"10.1016\/j.ymthe.2024.04.005_bib102","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1038\/nmeth.4237","article-title":"Generation of mature T\u00a0cells from human hematopoietic stem and progenitor cells in artificial thymic organoids","volume":"14","author":"Seet","year":"2017","journal-title":"Nat. Methods"}],"container-title":["Molecular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624002211?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1525001624002211?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T20:24:46Z","timestamp":1776803086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1525001624002211"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6]]},"references-count":102,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,6]]}},"alternative-id":["S1525001624002211"],"URL":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.04.005","relation":{},"ISSN":["1525-0016"],"issn-type":[{"value":"1525-0016","type":"print"}],"subject":[],"published":{"date-parts":[[2024,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Engineering allorejection-resistant CAR-NKT cells from hematopoietic stem cells for off-the-shelf cancer immunotherapy","name":"articletitle","label":"Article Title"},{"value":"Molecular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ymthe.2024.04.005","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors.","name":"copyright","label":"Copyright"}]}}